Volume 21, Number 4—April 2015
Dispatch
Safety of Recombinant VSV–Ebola Virus Vaccine Vector in Pigs
Table
Inoculum | Clinical signs | VSV lesions | Virus shedding from |
Viremia | Virus replication in tissues | Seroconversion at 21 dpi |
|||
---|---|---|---|---|---|---|---|---|---|
Nose | Throat | Rectum | VSV-G | EBOVGP | |||||
Mock (control) | ND | ND | ND | ND | ND | ND | ND | ND | ND |
rVSVwt | ND | 1/5† | ND | ND | ND | ND | 2/5‡ | 2/2 | ND |
rVSV∆G/EBOVGP | ND | ND | ND | 1/6§ | ND | ND | 2/6¶ | ND | 3/3 |
*rVSVwt, recombinant wild-type vesicular stomatitis virus; rVSV∆G/EBOVGP, recombinant VSV expressing Ebola virus strain Mayinga glycoprotein; VSV-G, VSV glycoprotein; dpi, day postinoculation; ND, not detected.
†Lesion at inoculation site.
‡Snout positive in virus titration in 2 of 3 animals at 3 dpi.
§One swab collected from 1 animal positive at 3 dpi.
¶Snout positive in 1 of 3 animals at 3 dpi; inguinal lymph node positive in 1 of 3 animals at 3 dpi.
1Current affiliation: University of Colorado, Boulder, Colorado, USA.
Page created: March 17, 2015
Page updated: March 17, 2015
Page reviewed: March 17, 2015
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.